Sinovac Biotech, Ltd. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (29)

Latest Posts

About This Stock More About This Stock
These Are Some Of The Coronavirus Vaccine Candidates
Article By: ValueWalk
Monday, May 25, 2020 6:28 PM EDT
As far as which coronavirus vaccine candidates will be tested first, researchers will look at production capacity and the amount of immune response generated in early trials and animal studies.
In this article: GSK, PFE, SNY, MRNA, ALT, JNJ, SVA, NVAX, INO, AZN
Week In Review: Leo Pharma Acquires Atopic Dermatitis Candidate From Taiwan-China Company In $570 Million Deal
Article By: ChinaBio® Today
Saturday, April 18, 2020 4:41 PM EDT
Leo Pharma, a Denmark dermatology company, acquired global rights to a novel treatment for atopic dermatitis (AD) and allergic asthma in an agreement worth up to $570 million. Leo acquired FB825 from Oneness Biotech of Taiwan and Microbio Shanghai.
In this article: SVA, BGNE
Week In Review: Eddingpharm To Pay $375 Million For Two Lilly Antibiotics And A Suzhou Manufacturing Facility
Article By: ChinaBio® Today
Saturday, April 27, 2019 4:20 PM EDT
Eddingpharm, a Hong Kong-headquartered China in-licensing company, agreed to pay $375 million to acquire China rights for two off-patent antibiotics from Lilly and the Suzhou factory that makes the antibiotics.
In this article: LLY, SVA
Week In Review: Suzhou Innovent Files For HK IPO -- $500 Million Raise Rumored
Article By: ChinaBio® Today
Saturday, July 7, 2018 4:06 PM EDT
Innovent Biologics of Suzhou has filed to IPO on the Hong Kong Exchange under its new rules for pre-revenue biopharmas. The company plans to raise as much as $500 million, according to media reports, at a valuation of over $1 billion.
In this article: LLY, SNY, SVA, BABA, ATNX
Week In Review: Another Billion Dollar Week For China Life Science Deals
Article By: ChinaBio® Today
Saturday, September 30, 2017 5:55 PM EDT
Shanghai Pharma Holding (SHA: 601607) may acquire part of Alvogen -- possibly Alvogen's US operations -- according to Bloomberg. Alvogen is a US-based generic drug maker thought to be worth as much as $4 billion.
In this article: NVO, SNY, SVA, AMGN, GILD, ZLAB, TSRO

Latest Tweets for $SVA

No tweets yet!